Sanjeev Nanda Eyeing to Uplift the Russian Pharmaceutical Infrastructure with ISHVAN Pharmaceuticals Limited

Sanjeev Nanda, a famous Indian restaurateur and hotelier, now a Dubai based entrepreneur, invests in ISHVAN Pharmaceuticals Limited to revive the local pharmaceutical infrastructure in Russia. The main aim of the pharmaceutical company will be to develop, manufacture and offer a varied range of innovative and affordable medical equipments, diagnostics and medical drugs to new pharmaceutical markets around the world.

Sanjeev Nanda, an entrepreneur with vast expertise and experience played a pivotal role in establishing the Taj Hotel at Dubai which is situated in Burj Khalifa Street. Apart from that, he also had a significant role to play in setting up “Billionaire Mansion” at the Taj Hotel Dubai, which serves as a unique dining venue, offering original Italian cuisine to its guests and partnered with award winning Japanese restaurant, SUMOSAN. Sanjeev Nanda has immense experience when it comes to running large organizations extended across various sectors such as heavy engineering, F&B, hotel & hospitality, IT and others. He was also the mastermind behind the creation of the well-known “Dhaba” which served as a unique charm of “The Claridges” hotel, also co-owned by Sanjeev Nanda. But on Dec’ 2016, the Dhaba by Claridges was sold to Azure Hospitality where Goldman Sachs and Max Ventures & Industries Limited are the investors. 

A 2-phased approach will be adopted by ISHVAN Pharmaceuticals Limited to attain its ambitions. In the first phase, the pharmaceutical markets of Russia and Eurasia will be the primary targets whereas in the next phase, it will turn its attention towards the Asian and African pharmaceutical markets. By bringing in turn-key solutions and expertise, the company will try to establish itself as a noteworthy player to develop the local Russian full-cycle infrastructure and offer access to recent generation products in HIV, Tuberculosis and Hepatitis. ISHVAN has already signed the Memorandum of Understanding (MoU) with National Immunobiological Company and started advanced negotiations with Russian and Indian companies to identify a way forward procedure. Some of the companies in India through which ISHVAN will acquire the technology required for production and development of drug substances (API) and finished drugs (FDF) include Mylan, Laurus, Cipla, etc. Also, the pharmaceutical firm has acquired market authorization (MA) from Rowtec and Cannon which will further create opportunities for product based revenue streams in the present and also the near future.

ISHVAN will presently pay attention to some niche segments like HIV/AIDS, Hepatitis and TB where the market size is expected to be $420 million. According to reports put forth by different agencies, Russia is the eighth most HIV populated country in the world where nearly seventy percent of the patients don’t have access to medical drugs and ISHVAN’s initiative will definitely help Russia take care of this growing epidemic. ISHVAN will aim towards introducing latest generation of medical products into the Russian market so as to achieve better treatment goals at reasonable prices. In its next phase of development, ISHVAN headed by Sanjeev Nanda will shift its attention towards bringing innovative therapy options and developing new platforms for areas like vaccines, blood products, oncology as well as biological drugs. Also ISHVAN will try to establish API production of its own within the Russian Federation to eliminate its dependency on suppliers from outside the country. All these efforts will certainly help in discovering and manufacturing effective vaccines, medicines and services which will improve the well-being of patients. It will also contribute significantly towards protection and quality of life as well as make further advances in global health issues.